@article{b563b51eb4d44cc79227c684dcb95b07,
title = "Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B",
abstract = "Individuals with chronic hepatitis B virus (HBV) infection who are at substantial risk of HIV acquisition benefit from pre-exposure prophylaxis (PrEP) with tenofovir-based antiviral therapy. Considering that tenofovir potently inhibits HBV, providing PrEP to individuals with HBV effectively results in treatment of their HBV infection. However, some clinicians might be hesitant to initiate PrEP in people with chronic HBV due to unknown risks of HBV reactivation, hepatitis, and acute liver failure during periods of antiviral cessation. Unfortunately, these knowledge gaps affect scale up of PrEP among people with chronic HBV. Emerging data regarding the risks and benefits of antiviral cessation in people with chronic HBV suggest that PrEP can be safely initiated despite the risks of non-adherence or discontinuation. People with chronic HBV who stop PrEP should be closely monitored for HBV reactivation and hepatitis flares after antiviral cessation.",
author = "Mohareb, {Amir M.} and Joseph Larmarange and Kim, {Arthur Y.} and Coffie, {Patrick A.} and Kouam{\'e}, {Menan G. rard} and Anders Boyd and Freedberg, {Kenneth A.} and Hyle, {Emily P.}",
note = "Funding Information: AMM is supported by the Massachusetts General Hospital (MGH) Executive Committee on Research Fund for Medical Discovery and the Charles A. King Trust Fellowship Program. AMM is also supported by the Harvard University Center for AIDS Research, a programme funded by the National Institutes of Health (NIH; P30 AI060354), which is supported by the following NIH co-funding and participating institutes and centres: National Institute of Allergy and Infectious Diseases; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Development; National Institute of Dental and Craniofacial Research; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Mental Health, National Institute on Aging, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Nursing Research, National Institute on Minority Health and Health Disparities, Fogarty International Center, and Office of AIDS Research. EPH is supported by the NIH (R37AI058736 and R01AI042006), the Harvard University Center for AIDS Research, and the Jerome and Celia Reich Endowed Scholar in HIV/AIDS Research at MGH. KAF is supported by the NIH (R37AI058736 and R01AI042006). The MGH Executive Committee on Research, Charles A King Trust Fellowship, Harvard University Center for AIDS Research, and the NIH had no role in the design or authorship of this Review. The article contents are solely the responsibility of the authors and do not necessarily represent the official views of the funders. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2022",
month = aug,
day = "1",
doi = "https://doi.org/10.1016/S2352-3018(22)00123-0",
language = "English",
volume = "9",
pages = "e585--e594",
journal = "The Lancet HIV",
issn = "2352-3018",
publisher = "Elsevier Limited",
number = "8",
}